1. Home
  2. CYBN vs JYNT Comparison

CYBN vs JYNT Comparison

Compare CYBN & JYNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CYBN
  • JYNT
  • Stock Information
  • Founded
  • CYBN 2019
  • JYNT 2010
  • Country
  • CYBN Canada
  • JYNT United States
  • Employees
  • CYBN N/A
  • JYNT N/A
  • Industry
  • CYBN Pharmaceuticals and Biotechnology
  • JYNT Multi-Sector Companies
  • Sector
  • CYBN Health Care
  • JYNT Miscellaneous
  • Exchange
  • CYBN Nasdaq
  • JYNT Nasdaq
  • Market Cap
  • CYBN 176.5M
  • JYNT 149.5M
  • IPO Year
  • CYBN N/A
  • JYNT 2014
  • Fundamental
  • Price
  • CYBN $5.94
  • JYNT $8.19
  • Analyst Decision
  • CYBN Strong Buy
  • JYNT Strong Buy
  • Analyst Count
  • CYBN 3
  • JYNT 3
  • Target Price
  • CYBN $85.00
  • JYNT $16.33
  • AVG Volume (30 Days)
  • CYBN 700.6K
  • JYNT 104.0K
  • Earning Date
  • CYBN 11-12-2025
  • JYNT 11-06-2025
  • Dividend Yield
  • CYBN N/A
  • JYNT N/A
  • EPS Growth
  • CYBN N/A
  • JYNT N/A
  • EPS
  • CYBN N/A
  • JYNT N/A
  • Revenue
  • CYBN N/A
  • JYNT $53,449,713.00
  • Revenue This Year
  • CYBN N/A
  • JYNT $7.70
  • Revenue Next Year
  • CYBN N/A
  • JYNT $10.24
  • P/E Ratio
  • CYBN N/A
  • JYNT N/A
  • Revenue Growth
  • CYBN N/A
  • JYNT 277.36
  • 52 Week Low
  • CYBN $4.81
  • JYNT $8.01
  • 52 Week High
  • CYBN $13.88
  • JYNT $13.47
  • Technical
  • Relative Strength Index (RSI)
  • CYBN 45.57
  • JYNT 22.68
  • Support Level
  • CYBN $5.93
  • JYNT $8.04
  • Resistance Level
  • CYBN $6.63
  • JYNT $9.93
  • Average True Range (ATR)
  • CYBN 0.32
  • JYNT 0.30
  • MACD
  • CYBN 0.03
  • JYNT -0.10
  • Stochastic Oscillator
  • CYBN 30.77
  • JYNT 9.33

About CYBN Cybin Inc.

Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.

About JYNT The Joint Corp.

The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The Company has one operating business segment; The Franchise Operations segment which is comprised of the operating activities of the franchise business unit. The Franchise Operations segment derives revenue from customers by providing access to the Company's franchise license, which represents symbolic intellectual property.

Share on Social Networks: